期刊文献+

闰年霉素晶体的制备及稳定性研究

Preparation and Stability of Lipiarmycin Crystal
下载PDF
导出
摘要 以闰年霉素无定形粉为原料,以闰年霉素结晶粉纯度和收率为评价指标,进行结晶参数优化,开发了一种闰年霉素晶体制备方法,通过扫描电镜、粒度分析仪、X-射线衍射仪对闰年霉素晶体进行表征,并通过加速稳定性实验对其稳定性进行评价。结果表明,以75%甲醇为结晶溶剂,在料液比为1∶20(g∶mL)、结晶温度为2~10℃的条件下,可以得到柱状、均匀规整、粒度分布集中、稳定性好的闰年霉素晶体。该方法操作简单、收率高、可行性强,适于工业化生产。 Using Lipiarmycin amorphous powder as a raw material,the purity and yield of Lipiarmycin crystal powder as evaluation indexes,we optimized the crystallization parameters,and developed a preparation method of Lipiarmycin crystal.Moreover,we characterized the Lipiarmycin crystal by SEM,particle size distribution,and XRD.Furthermore,we evaluated the stability of the Lipiarmycin crystal by accelerated stability experiments.The results show that the columnar,uniform,and regular Lipiarmycin crystal with concentrated particle size distribution and good stability can be obtained under the optimum conditions as follows:75%methanol is adopted as the crystallization solvent,the solid-liquid ratio is 1∶20(g∶mL),and the crystallization temperature is 2-10℃.The method has the advantages of simple operation,high yield,and strong feasibility,which is suitable for industrial production.
作者 王月 王欣明 高月麒 张丽 林旸 李晓露 WANG Yue;WANG Xinming;GAO Yueqi;ZHANG Li;LIN Yang;LI Xiaolu(National Engineering Research Center of Microbial Medicine,Hebei Industry Microbial Metabolic Engineering & Technology Research Center,New Drug Research & Development Co.,Ltd.of NCPC,Shijiazhuang 052165,China;North China Pharmaceutical Co.,Ltd.,Shijiazhuang 050015,China)
出处 《化学与生物工程》 CAS 2021年第8期44-47,共4页 Chemistry & Bioengineering
基金 河北省科技研发平台建设专项(199676154H)。
关键词 闰年霉素 晶体 制备 稳定性 Lipiarmycin crystal preparation stability
  • 相关文献

参考文献6

二级参考文献99

  • 1冒莉,郑启泰,吕扬.固体药物多晶型的研究进展[J].天然产物研究与开发,2005,17(3):371-375. 被引量:48
  • 2何元.在线监测化合物结晶的先进技术——在线颗粒度监测[J].中国医药工业杂志,2006,37(4). 被引量:2
  • 3马廷升,朱兰翠.药物生物利用度影响因素的动态分析[J].怀化学院学报,2006,25(2):76-77. 被引量:6
  • 4张伟国,刘昌孝.多晶型药物的生物利用度研究概况[J].天津药学,2007,19(2):59-61. 被引量:13
  • 5王彩娟.2006年全球药品市场分析[J].世界临床药物,2007,28(8):510-512. 被引量:1
  • 6郑丽莉.The effect of pharmaceutical polymorph for the quality of drugs[J]China Pharmacist (中国药师),2008(03):347-349.
  • 7Jiang Shanfeng,Pieter J Jansens,Joop Hter Horst. Control over polymorph formation of o-aminobenzoic acid[J].Crystal Growth and Design,2010.2541-2547.
  • 8Martínez-Ohárriz M C,Martín C,Go(n)i M M,RodríguezEspinosa C Tros De Ilarduya-Apaolaza M C Sánchez M. Polymorphism of diflunisal:isolation and solid-state characteristics of a new crystal form[J].Journal of Pharmaceutical Sciences,1994,(02):174-177.
  • 9Damir Kralj,Ljerka Brecevic,Jasminka Kontrec. Vaterite growth and dissolution in aqueous solution (Ⅲ):Kinetics of transformation[J].Journal of Crystal Growth,1997.248-257.
  • 10Davey R J,Blagden N,Righini S,Alison H Ferrari E S. Nucleation control in solution mediated polymorphic phase transformations:the case of 2,6-dihydroxybenzoic acid[J].The Journal of Physical Chemistry(B)Materials Surfaces Interfaces & Physical,2001,(08):1954-1959.

共引文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部